Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Lifestyle Factors, Colorectal Tumor Methylation, and Survival Among African Americans and European Americans.

Busch EL, Galanko JA, Sandler RS, Goel A, Keku TO.

Sci Rep. 2018 Jun 21;8(1):9470. doi: 10.1038/s41598-018-27738-x.

2.

Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy.

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P.

Clin Cancer Res. 2018 Jun 19. pii: clincanres.0866.2018. doi: 10.1158/1078-0432.CCR-18-0866. [Epub ahead of print]

PMID:
29921730
3.

JAB1-STAT3 activation loop is associated with recurrence following 5-fluorouracil-based adjuvant chemotherapy in human colorectal cancer.

Kugimiya N, Nishimoto A, Hosoyama T, Ueno K, Takemoto Y, Harada E, Enoki T, Hamano K.

Oncol Lett. 2017 Nov;14(5):6203-6209. doi: 10.3892/ol.2017.6994. Epub 2017 Sep 18.

4.

Inflammation-driven colon neoplasmatogenesis in uPA-deficient mice is associated with an increased expression of Runx transcriptional regulators.

Afaloniati H, Karagiannis GS, Hardas A, Poutahidis T, Angelopoulou K.

Exp Cell Res. 2017 Dec 15;361(2):257-264. doi: 10.1016/j.yexcr.2017.10.025. Epub 2017 Oct 26.

PMID:
29107070
5.

CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.

Vedeld HM, Merok M, Jeanmougin M, Danielsen SA, Honne H, Presthus GK, Svindland A, Sjo OH, Hektoen M, Eknaes M, Nesbakken A, Lothe RA, Lind GE.

Int J Cancer. 2017 Sep 1;141(5):967-976. doi: 10.1002/ijc.30796. Epub 2017 Jun 2.

6.

The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.

Cohen SA, Yu M, Baker K, Redman M, Wu C, Heinzerling TJ, Wirtz RM, Charalambous E, Pentheroudakis G, Kotoula V, Kalogeras KT, Fountzilas G, Grady WM.

Clin Epigenetics. 2017 May 2;9:46. doi: 10.1186/s13148-017-0347-1. eCollection 2017.

7.

Genetic variants in the TGFβ-signaling pathway influence expression of miRNAs in colon and rectal normal mucosa and tumor tissue.

Slattery ML, Trivellas A, Pellatt AJ, Mullany LE, Stevens JR, Wolff RK, Herrick JS.

Oncotarget. 2017 Mar 7;8(10):16765-16783. doi: 10.18632/oncotarget.14508.

8.

Cytoplasmic Localization of RUNX3 via Histone Deacetylase-Mediated SRC Expression in Oxidative-Stressed Colon Cancer Cells.

Kang KA, Piao MJ, Ryu YS, Maeng YH, Hyun JW.

J Cell Physiol. 2017 Jul;232(7):1914-1921. doi: 10.1002/jcp.25746. Epub 2017 Feb 21.

PMID:
27990641
9.

RUNX3 inhibits the metastasis and angiogenesis of colorectal cancer.

Kim BR, Kang MH, Kim JL, Na YJ, Park SH, Lee SI, Kang S, Joung SY, Lee SY, Lee DH, Min BW, Oh SC.

Oncol Rep. 2016 Nov;36(5):2601-2608. doi: 10.3892/or.2016.5086. Epub 2016 Sep 12.

PMID:
27633042
10.

CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis.

Scarpa M, Scarpa M, Castagliuolo I, Erroi F, Basato S, Brun P, Angriman I, Castoro C.

BMC Cancer. 2016 Jul 4;16:388. doi: 10.1186/s12885-016-2405-z.

11.

A Biomarker Panel to Detect Synchronous Neoplasm in Non-neoplastic Surveillance Biopsies from Patients with Ulcerative Colitis.

Garrity-Park MM, Loftus EV Jr, Bryant SC, Smyrk TC.

Inflamm Bowel Dis. 2016 Jul;22(7):1568-74. doi: 10.1097/MIB.0000000000000789.

PMID:
27135485
12.

Localization of specialized intestinal metaplasia and the molecular alterations in Barrett esophagus in a Japanese population: an analysis of biopsy samples based on the "Seattle" biopsy protocol.

Fukui S, Watari J, Tomita T, Yamasaki T, Okugawa T, Kondo T, Kono T, Tozawa K, Ikehara H, Ohda Y, Oshima T, Fukui H, Das KM, Miwa H.

Hum Pathol. 2016 May;51:32-40. doi: 10.1016/j.humpath.2015.12.013. Epub 2016 Jan 7.

13.
14.

Aberrant gene methylation in non-neoplastic mucosa as a predictive marker of ulcerative colitis-associated CRC.

Scarpa M, Scarpa M, Castagliuolo I, Erroi F, Kotsafti A, Basato S, Brun P, D'Incà R, Rugge M, Angriman I, Castoro C.

Oncotarget. 2016 Mar 1;7(9):10322-31. doi: 10.18632/oncotarget.7188.

15.

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.

Cohen SA, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G, Gkakou C, Kotoula V, Pentheroudakis G, Papaxoinis G, Karavasilis V, Pectasides D, Kalogeras KT, Fountzilas G, Grady WM.

Clin Colorectal Cancer. 2016 Jun;15(2):164-9. doi: 10.1016/j.clcc.2015.10.005. Epub 2015 Nov 11.

16.

Investigation of methylation and protein expression of the Runx3 gene in colon carcinogenesis.

He SY, Jiang RF, Jiang J, Xiang YS, Wang L.

Biomed Rep. 2015 Sep;3(5):687-690. Epub 2015 Jun 17.

17.

Integrative genomic analyses of the RNA-binding protein, RNPC1, and its potential role in cancer prediction.

Ding Z, Yang HW, Xia TS, Wang B, Ding Q.

Int J Mol Med. 2015 Aug;36(2):473-84. doi: 10.3892/ijmm.2015.2237. Epub 2015 Jun 5.

PMID:
26046131
18.

Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.

Kim JH, Cho NY, Bae JM, Kim KJ, Rhee YY, Lee HS, Kang GH.

Int J Clin Exp Pathol. 2015 Feb 1;8(2):1920-8. eCollection 2015.

19.

Differential expressions of cancer-associated genes and their regulatory miRNAs in colorectal carcinoma.

Kara M, Yumrutas O, Ozcan O, Celik OI, Bozgeyik E, Bozgeyik I, Tasdemir S.

Gene. 2015 Aug 1;567(1):81-6. doi: 10.1016/j.gene.2015.04.065. Epub 2015 Apr 27.

PMID:
25925209
20.

Molecular subtypes in stage II-III colon cancer defined by genomic instability: early recurrence-risk associated with a high copy-number variation and loss of RUNX3 and CDKN2A.

Berg M, Nordgaard O, Kørner H, Oltedal S, Smaaland R, Søreide JA, Søreide K.

PLoS One. 2015 Apr 16;10(4):e0122391. doi: 10.1371/journal.pone.0122391. eCollection 2015.

Supplemental Content

Loading ...
Support Center